Tolerance of vancomycin for surgical prophylaxis in patients undergoing cardiac surgery and incidence of vancomycin-resistant enterococcus colonization
- PMID: 16478809
- DOI: 10.1345/aph.1G565
Tolerance of vancomycin for surgical prophylaxis in patients undergoing cardiac surgery and incidence of vancomycin-resistant enterococcus colonization
Abstract
Background: In 2001, vancomycin replaced cefuroxime for antibiotic prophylaxis in patients undergoing cardiac surgery at our institution due to high rates of surgical site infections caused by methicillin-resistant Staphylococcus spp. However, few data supported the use of vancomycin for surgical prophylaxis.
Objective: To determine the tolerance of vancomycin for antibiotic prophylaxis and incidence of vancomycin-resistant Enterococcus (VRE) in cardiac surgery patients.
Methods: In 2 separate studies, we assessed the adverse effects in patients given perioperative vancomycin (study 1) and the incidence of VRE in patients given perioperative vancomycin (study 2). Study 1 was a prospective cohort study of patients undergoing coronary artery bypass graft (CABG) or valve replacement surgery given vancomycin (1 dose preoperatively/2 doses postoperatively) for antibiotic prophylaxis between October 2003 and December 2004. Patients were assessed for tolerance to the antibiotic regimen. In study 2, cardiac surgery patients receiving perioperative vancomycin were screened for VRE before therapy and at day 7 of hospitalization. VRE was detected using standard microbiologic procedures.
Results: In study 1, 1161 patients (CABG = 75%; valve = 19%; both = 6%) were evaluated. All patients but one (99.9%) were prescribed preoperative vancomycin. Therapy was changed for 34 (2.9%) patients, of which 20 changes were due to physician preference for another antibiotic. The only toxicity that required a change in the vancomycin regimen was red man's syndrome, which was experienced by 9 (0.8%) patients. Four patients did not receive a second postoperative dose due to prior renal insufficiency. Patients were most commonly switched to cefuroxime (n = 26), linezolid (n = 2), cefepime (n = 2), gatifloxacin, cefazolin, levofloxacin, or ceftriaxone (n = 1, each). In study 2, 100 patients were screened for the emergence of VRE colonization. No patient was VRE positive at baseline and 4 (4%) were positive at day 7.
Conclusions: Surgical antibiotic prophylaxis with vancomycin was reasonably well tolerated in CABG and valve replacement surgery, with a 4% incidence of VRE colonization.
Similar articles
-
Comparative study of cefazolin, cefamandole, and vancomycin for surgical prophylaxis in cardiac and vascular operations. A double-blind randomized trial.J Thorac Cardiovasc Surg. 1992 Nov;104(5):1423-34. J Thorac Cardiovasc Surg. 1992. PMID: 1434726 Clinical Trial.
-
Timing of vancomycin prophylaxis for cardiac surgery patients and the risk of surgical site infections.J Antimicrob Chemother. 2006 Sep;58(3):645-50. doi: 10.1093/jac/dkl279. Epub 2006 Jun 27. J Antimicrob Chemother. 2006. PMID: 16807254 Clinical Trial.
-
Economic benefit of appropriate timing of vancomycin prophylaxis in patients undergoing cardiovascular surgery.Pharmacotherapy. 2008 Jun;28(6):699-706. doi: 10.1592/phco.28.6.699. Pharmacotherapy. 2008. PMID: 18503397
-
Endocarditis due to vancomycin-resistant enterococci: case report and review of the literature.Clin Infect Dis. 2005 Oct 15;41(8):1134-42. doi: 10.1086/444459. Epub 2005 Sep 9. Clin Infect Dis. 2005. PMID: 16163631 Review.
-
Optimizing therapy for vancomycin-resistant enterococci (VRE).Semin Respir Crit Care Med. 2007 Dec;28(6):632-45. doi: 10.1055/s-2007-996410. Semin Respir Crit Care Med. 2007. PMID: 18095227 Review.
Cited by
-
Interrupted time series analysis of vancomycin compared to cefuroxime for surgical prophylaxis in patients undergoing cardiac surgery.Antimicrob Agents Chemother. 2008 Feb;52(2):446-51. doi: 10.1128/AAC.00495-07. Epub 2007 Nov 19. Antimicrob Agents Chemother. 2008. PMID: 18025116 Free PMC article.
-
The use of broad-spectrum antibiotics reduces the incidence of surgical site infection after pancreatoduodenectomy.Surg Today. 2018 Sep;48(9):825-834. doi: 10.1007/s00595-018-1658-3. Epub 2018 Apr 23. Surg Today. 2018. PMID: 29687153
-
Impact of methicillin-resistant Staphylococcus aureus prevalence among S. aureus isolates on surgical site infection risk after coronary artery bypass surgery.Infect Control Hosp Epidemiol. 2011 Apr;32(4):342-50. doi: 10.1086/658668. Infect Control Hosp Epidemiol. 2011. PMID: 21460485 Free PMC article.
-
Preventing deep wound infection after coronary artery bypass grafting: a review.Tex Heart Inst J. 2013;40(2):125-39. Tex Heart Inst J. 2013. PMID: 23678210 Free PMC article. Review.
-
Multicentre randomised double-blind placebo controlled trial of combination vancomycin and cefazolin surgical antibiotic prophylaxis: the Australian surgical antibiotic prophylaxis (ASAP) trial.BMJ Open. 2019 Nov 3;9(11):e033718. doi: 10.1136/bmjopen-2019-033718. BMJ Open. 2019. PMID: 31685516 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous